The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Cesar Augusto Perez
Consulting or Advisory Role - BeiGene; EMD Serono
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); Elevation Oncology; Elevation Oncology; Elpiscience (Inst); Genentech; Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Merus; Mirati Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Tachyon Therapeutics; Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Sreenivasa R Chandana
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BMS (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Zymeworks (Inst)
 
Nataliya Volodymyrivna Uboha
Stock and Other Ownership Interests - Exact Sciences (I); Natera (I)
Consulting or Advisory Role - Aptitude Health; Astellas Pharma; Astellas Pharma; AstraZeneca; BostonGene; Bristol Myers Squibb Foundation; Bristol-Myers Squibb/Roche; Eisai/MSD; Elevation Oncology; GRAIL; Helsinn Therapeutics; Ipsen; ipsen; Pfizer
Research Funding - EMD Serono (Inst); ipsen (Inst)
 
Ashwin Swami
Employment - Elevation Oncology
Stock and Other Ownership Interests - Elevation Oncology
Consulting or Advisory Role - X4 Pharma
 
Holly McDonald
Employment - Elevation Oncology
Stock and Other Ownership Interests - Elevation Oncology
 
Jaya Srivastava
Employment - Elevation Oncology
Stock and Other Ownership Interests - Elevation Oncology
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas